2022 World Conference on Lung Cancer (ePosters)-EP14.01-002. Efficacy and Safety of Tiselizumab Combined with Anlotinib and 2-cycle Irinotecan as Second-line Treatment of Small Cell Lung Cancer

EP14.01-002. Efficacy and Safety of Tiselizumab Combined with Anlotinib and 2-cycle Irinotecan as Second-line Treatment of Small Cell Lung Cancer

Back to course

Pdf Summary

The ESTAIL study aims to evaluate the efficacy and safety of Tislelizumab, Anlotinib, and Irinotecan as second-line treatment for patients with relapsed extensive stage small cell lung cancer (ES-SCLC) after platinum-based chemotherapy. ES-SCLC is often treated with chemotherapy as a second-line therapy, but the outcomes are usually poor. The study is based on previous findings that combining anti-angiogenic drugs with PD-1 inhibitors can improve anti-tumor activity. The CheckMate9LA study has also shown that combining immune checkpoint inhibitors with chemotherapy can improve short-term efficacy.<br /><br />In the Rational 206 study, the combination of Tislelizumab with chemotherapy showed promising activity in patients with ES-SCLC who were naïve to anti-PD-L1 immunotherapy. The primary endpoint of the ESTAIL study is the assessment of objective response rate (ORR) according to RECIST V1.1 by the investigator. Secondary endpoints include progression-free survival (PFS), overall survival (OS), disease control rate, and safety.<br /><br />The study design includes patients with ES-SCLC who have had disease progression after platinum-doublet chemotherapy and PD-L1 inhibitors. Patients must have an Eastern Cooperative Oncology Group performance status of 0 or 1 and measurable disease per RECIST V1.1. The treatment regimen consists of Tislelizumab, Anlotinib, and Irinotecan for 2 cycles.<br /><br />Assessments in the study include radiographic imaging for tumor response and survival follow-up after the subjects stop the trial. The study is sponsored by Beigene and CTTQ and is being conducted at the Guangdong Hospital of Traditional Chinese Medicine in Guangzhou, China.<br /><br />Overall, the ESTAIL study aims to investigate the efficacy and safety of the combination of Tislelizumab, Anlotinib, and Irinotecan as second-line treatment for relapsed ES-SCLC. The study design and eligibility criteria are outlined, and the endpoints and assessments are described.

Asset Subtitle

Xian Chen

Meta Tag

Speaker Xian Chen

Topic Small Cell Lung Cancer and Neuro-endocrine Tumours - Informing ES-SCLC

Keywords

ESTAIL study

Tislelizumab

Anlotinib

Irinotecan

relapsed extensive stage small cell lung cancer

ES-SCLC

platinum-based chemotherapy

anti-angiogenic drugs

PD-1 inhibitors

CheckMate9LA study